Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹7,868 Cr
verified against source
Revenue YoY
4%
reported change
EBITDA
₹1,603 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Aurobindo Pharma reported a steady Q1 FY26 with consolidated revenue of INR 7,878 crore (+4% YoY) and EBITDA of INR 1,603 crore (+12% YoY), despite a significant reduction in generic Revlimid sales (down ~INR 150 crore YoY). EBITDA margin held at 20.4%, supported by favorable mix and cost controls. European formulations grew 9% YoY to €241 million, while the U.S. business declined 4% due to Revlimid erosion and temporary destocking. API revenue fell 16% YoY on pricing pressure. Management maintained FY26 EBITDA margin guidance of 20-21%, driven by ramp-up of the PNG plant (resumed July 1) and new capacity additions. Key risks include sustained API pricing pressure and FTC approval delays for the Lannett acquisition.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated internal target margin range of 20-21% for FY26, supported by volume expansion and new site ramp-up.
- The China facility, with initial capacity of 2 billion+ units, is expected to break even at EBITDA level by Q3 FY26.
- The PNG plant resumed operations and is expected to generate healthy EBITDA from Q3 onwards as yields improve.
- Management expects European formulations to exceed €1 billion in annual revenues by the end of FY26.
Risks flagged
- API revenue declined 16% YoY due to pricing pressure from both domestic and import competition, which may persist.
- The Lannett acquisition is subject to FTC approval, which could take 8-12 months or longer, delaying synergies.
- Generic Revlimid sales have largely been exhausted, with minimal future contribution expected, impacting U.S. revenue.
- Potential U.S. tariffs and push for domestic manufacturing could increase costs and alter competitive dynamics.
Key quotes
- We have most of our generic Revlimid settlement quantities. We have sold it. We have nothing more to sell other than a minimal listing.
- We are confident of achieving our internal target margin of 20% to 21% range in FY 2026.
- We are best suited for enhancing our footprint in the U.S. Practically, if it's manufactured in the U.S., the product pricing would go up higher.
Research modules